Fluorinov Pharma to Develop Oral Multiple Myeloma Drug
BioWorld Insight Editor
Following on from the success of the approved first-generation proteasome inhibitor Velcade (bortezomib, Millennium/Takeda Pharmaceutical Co. Ltd.), which jams up the proteasome and nonspecifically inhibits proteins from being degraded, various new proteasome inhibitors are currently in development, including peptide boronic acid analogue MLN9708 (Millennium/Takeda) and carfilzomib (Onyx Pharmaceuticals Inc.).
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST